PDS Biotechnology redeemed its Yorkville Promissory Note for approximately $4.6 million, terminating the debt instrument. Concurrently, the company closed a PIPE financing led by Nant Capital, raising gross proceeds of $11.3 million through the issuance of common stock and warrants at a unit price of $0.2825. As part of the transaction, Dr. Patrick Soon-Shiong and Mr. James Banaag were appointed to the Board of Directors, with Nant securing designation rights contingent on maintaining a 15% ownership stake. The company also granted NantWorks an exclusive option to negotiate a license for its PDS0101 compound. PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies and cancer vaccines.

PDS Biotechnology Corporation entered into a Securities Purchase Agreement for an unregistered private placement of up to $22.55 million in equity funding, led by Nant Capital, LLC. The transaction includes an initial closing expected on September 11, 2026, generating approximately $11.55 million from the sale of common stock and warrants at a unit price of $0.2825. A contingent milestone closing will occur upon FDA submission of a Phase 3 protocol for PDS0301, obligating Nant and AB Group Ltd. to purchase an additional $11 million in securities. In connection with the financing, the board size increased from six to eight directors, granting Nant the right to designate two members, including Dr. Patrick Soon-Shiong, provided it retains 15% ownership. The company also granted NantWorks a one-year exclusive option to negotiate a license for its PDS0101 program. PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer.

PDS Biotechnology Corporation entered into a First Amendment to Promissory Note with YA II PN, Ltd., modifying the terms of a $6,000,000 promissory note originally issued on June 15, 2026. The amendment requires weekly remittance notices for net proceeds from at-the-market offerings and mandates that 100% of net cash proceeds from any other equity or equity-linked financing be applied as a mandatory deemed redemption to the holder within five business days. Additionally, the cure period for Nasdaq listing deficiencies was extended from 75 to 180 days. The amendment becomes effective upon execution and payment of the installment due on September 14, 2026. PDS Biotechnology Corporation operates in the biotechnology industry, focusing on developing immunotherapies.

PDS Biotechnology Corporation announced a reduction in force affecting approximately 36% of its workforce to align expenses with strategic priorities focused on PDS0301. The company expects to record a one-time charge of approximately $842,000 for employee separation benefits in the third quarter of 2026. Concurrently, the company terminated Stephan Toutain as Chief Operating Officer without cause. Mr. Toutain is entitled to severance comprising twelve months of base salary and COBRA health care contributions. PDS Biotechnology Corporation operates in the biopharmaceutical industry, developing treatments for rare diseases.

PDS Biotechnology Corp announced that Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer on August 13, 2026, effective September 12, 2026. The board appointed Janetta Trochimiuk as interim Principal Accounting Officer and Frank Bedu-Addo as interim Principal Financial Officer, both effective the same date. Boesgaard stated his departure is for other professional endeavors and not due to disagreements. Trochimiuk will retain her base salary of $279,519.57 annually without new equity awards. PDS Biotechnology Corp operates in the biopharmaceutical industry, developing therapies for cancer.